<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
    /* Dark mode support */
    @media (prefers-color-scheme: dark) {
      :root {
        --border: #374151;
        --muted: #9ca3af;
        --bg: #111827;
        --card: #1f2937;
        --soft: #374151;
        --accent: #60a5fa;
      }
      body { color: #f3f4f6; }
      h1, h2, h3 { color: #f9fafb; }
      table.grid th { background: #374151; color: #f3f4f6; }
      .refs-title { color: #f9fafb; }
      .ref-cat-header { background: linear-gradient(135deg, #374151 0%, #4b5563 100%); color: #f3f4f6; }
      .ref-entry { background: #374151; }
      .ref-details { color: #d1d5db; }
      .mermaid-chart { background: linear-gradient(135deg, #1f2937 0%, #374151 100%); }
      .stats-card { background: linear-gradient(135deg, #1e3a5f 0%, #1e293b 100%) !important; border-color: #0ea5e9 !important; }
      .stats-card h2 { color: #7dd3fc !important; }
    }
    /* Print button */
    .print-btn {
      position: fixed; top: 20px; right: 20px; z-index: 1000;
      padding: 10px 18px; cursor: pointer;
      background: linear-gradient(135deg, #2563eb 0%, #1d4ed8 100%);
      color: white; border: none; border-radius: 8px;
      font-size: 14px; font-weight: 600;
      box-shadow: 0 2px 8px rgba(37, 99, 235, 0.3);
      transition: all 0.2s ease;
    }
    .print-btn:hover { background: linear-gradient(135deg, #1d4ed8 0%, #1e40af 100%); transform: translateY(-1px); box-shadow: 0 4px 12px rgba(37, 99, 235, 0.4); }
    .print-btn:active { transform: translateY(0); }
    /* Print-friendly styles */
    @media print {
      body { margin: 0; background: white; }
      .card, details { border: 1px solid #ccc; page-break-inside: avoid; }
      details[open] > summary ~ * { display: block; }
      .mermaid-chart { page-break-inside: avoid; }
      .stats-card { background: #f0f9ff !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
      .no-print { display: none !important; }
    }
    /* Responsive layout */
    @media (max-width: 768px) {
      body { margin: 12px; }
      .cols { grid-template-columns: 1fr; }
      table.grid { font-size: 11px; }
      table.grid th, table.grid td { padding: 4px; }
    }
  </style>
</head>
<body>
  <button onclick="window.print()" class="print-btn no-print">ğŸ–¨ï¸ Print Report</button>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>ğŸ¯ Mode:</strong> <code style='background: #e0f2fe; padding: 2px 8px; border-radius: 4px; font-weight: 600;'>omgs</code>
</div>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 155.4 seconds (2åˆ†35ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 109,653</li>
<li>Output: 4,960</li>
<li>Total: 114,613</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>gpt-5.1 (Azure)</strong>: 
23 calls, 
114,613 tokens 
(109,653 in / 4,960 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-21_18-43-48</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Metastatic, platinumâ€‘resistant highâ€‘grade ovarian clear cell carcinoma with progressive hepatic, presacral/sacral, iliac bone and peritoneal disease; palliative intent. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]  
MMR intact, BRCA/HRD negative, germline ATM p.Y316C VUS; no current evidence of histologic transformation. [@OH2203828 | Genomics]  
Severe anemia (Hgb 74 g/L) and unknown ECOG/organ function are major constraints and must be clarified before systemicâ€‘therapy decisions. [@20230103|5600862 | LAB]

Core Treatment Strategy:
- Urgently investigate and correct anemia; perform iron/B12/folate, bleeding and hemolysis workup, and consider transfusion as indicated. [@20230103|5600862 | LAB]  
- Obtain full renal/LFT/coagulation panel and document ECOG PS and symptom/pain burden to define safe treatment intensity. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]  
- Restage with contrast CT chest/abdomen/pelvis to reassess metastatic burden and suspected splenic infarct before systemic changes. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]  
- Plan nonâ€‘platinum palliative systemic relapse therapy (or clinical trial) tailored to ECOG, organ function, and prior toxicities. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22] [@trial | 350]  
- Send MSI, TMB, PDâ€‘L1 CPS, HER2 (and extended HR genes if available) to refine current and future systemic options. [@OH2203828 | Genomics] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  
- Coordinate palliative radiotherapy and boneâ€‘directed management for symptomatic sacral/iliac/presacral and other bone lesions. [@2022-12-29|MR | MR]  
- Defer FDG PET/CT; consider only if results would change systemic plan or local palliative targeting (e.g., complex bone disease). [@pubmed | 23117032]  

Change Triggers:
- If ECOG â‰¤2 with corrected anemia and adequate organ function, proceed to fullâ€‘dose nonâ€‘platinum relapse systemic therapy or suitable trial. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22] [@trial | 350]  
- If ECOG â‰¥3, refractory anemia, or organ dysfunction persists, prioritize best supportive care, symptomâ€‘directed radiotherapy, and deâ€‘escalated systemic approach.</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: nccn_ovariancancer_v3_2025__v00000000, Page 22</div>
<div class='ref-detail-line'>Content: Survivorship)</div>
<div class='ref-detail-line'>Recurrent</div>
<div class='ref-detail-line'>diseaset</div>
<div class='ref-detail-line'>Hormonal...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 10</div>
<div class='ref-detail-line'>Content: with ï¬rst line. This can probably be explained by an...</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
<div class='ref-entry'>
<div class='ref-tag'>[@pubmed | 23117032]</div>
<div class='ref-details'>
<div class='ref-detail-line'>[Not cached]</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
<div class='ref-entry'>
<div class='ref-tag'>[@trial | 350]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Trial ID: 350</div>
<div class='ref-detail-line'>Name: è¯„ä»·æ³¨å°„ç”¨BL-B01D1åœ¨å¤å‘æˆ–è½¬ç§»æ€§å¦‡ç§‘æ¶æ€§è‚¿ç˜¤ç­‰å¤šç§å®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§ã€è¯ä»£åŠ¨åŠ›å­¦åŠæœ‰æ•ˆæ€§çš„Ib/IIæœŸä¸´åºŠç ”ç©¶</div>
<div class='ref-detail-line'>Rationale: Recurrent metastatic ovarian clear cell carcinoma after failure of first-line platinum chemotherapy fits a â‰¥2L recurrent/metastatic gynecologic malignancy trial without biomarker requirement.</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-12-29|MR | MR]</div>
<div class='ref-details'>
<div class='ref-detail-line'>MR ID: 2022-12-29|MR | Date: 2022-12-29</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-12-29|CT | CT]</div>
<div class='ref-details'>
<div class='ref-detail-line'>CT ID: 2022-12-29|CT | Date: 2022-12-29</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2203828 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2203828 | Date: 2022-04-18</div>
<div class='ref-detail-line'>Content: ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230103|5600862 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230103|5600862 | Date: 2023-01-03</div>
<div class='ref-detail-line'>Content: ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN) PLTåˆ†å¸ƒå®½åº¦ 12 % (PDW) å—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L...</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰æœ¯åç™½ç´«+å¡é“‚åŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡ï¼š2022.8.172022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)MRï¼ˆ2022.07.17ï¼‰ï¼š2022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.10.12ï¼‰ï¼šCA19-9:77.20U/mlâ†‘,CA125:89.60U/mlâ†‘,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(ç»ç»å‰)â†‘,ROMA.:36.67%(ç»ç»å)â†‘ã€‚CTï¼ˆ2022.10.25ï¼‰ï¼šè‚å†…å¤šå‘ç»“èŠ‚ï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ï¼Œè½¬ç§»å¯èƒ½ï¼Œè¯·ç»“åˆMRæ£€æŸ¥ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚MRï¼ˆ2022.10.24ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚2022.11.10å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 2.36ï¼Œçº¢ç»†èƒ 3.56ï¼Œè¡€çº¢è›‹ç™½ 97ï¼Œè¡€å°æ¿ 153å¤–é™¢ç”ŸåŒ–ï¼šALPã€€105ï¼ŒNA 136ï¼ŒPAB 1242022.11.30å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 3.46ï¼Œçº¢ç»†èƒ 3.48ï¼Œè¡€çº¢è›‹ç™½ 94ï¼Œè¡€å°æ¿ 1342022.11.17å¤–é™¢è‚¿ç˜¤æŒ‡æ ‡ï¼šCA125ã€€403ï¼ŒCa153ã€€63.8ï¼ŒCa199 96.8ï¼ŒCa724 695è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.12.29ï¼‰ï¼šCA19-9:229.00U/mlâ†‘,CA125:933.00U/mlâ†‘,CA15-3:86.00U/mlâ†‘,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/Lâ†‘,ROMA:41.02%(ç»ç»å‰)â†‘,ROMA.:85.98%(ç»ç»å)â†‘ã€‚MRï¼ˆ2022.12.30ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚CTï¼ˆ2022.12.30ï¼‰ï¼šè‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚å’¨è¯¢æŠ¥å‘Š</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;High-grade adenocarcinoma involving full-thickness intestinal wall&quot;,&quot;Lymph node metastasis (4/15)&quot;,&quot;Peritoneal/rectal/vaginal involvement described&quot;],&quot;histology&quot;:&quot;é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;åµå·¢ç™Œå¤å‘&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Unknown&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;ç™½ç´«+å¡é“‚&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;Rise in CA125/CA19-9 on 2022-10-12&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery performed&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising tumor markers&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;6 cycles of ç™½ç´«+å¡é“‚, last 2022-08-17&quot;,&quot;last_admin_date&quot;:&quot;2022-08-17&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;Tumor size ~7x4x2.5 cm&quot;,&quot;Bilateral margins negative&quot;,&quot;Pericolic lymph nodes 4/15 positive&quot;,&quot;One tumor nodule (posterior bladder)&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;partial+&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;few weak+&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;+/-&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;60%+&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;focal+&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;-&quot;}],&quot;involvement_sites&quot;:[&quot;Rectosigmoid colon&quot;,&quot;Left retroperitoneum&quot;,&quot;Vagina&quot;,&quot;Pericolic lymph nodes&quot;,&quot;Posterior bladder nodule&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562 2022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7 x 4 x 2.5 cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;BRCA/HRD testing not reported&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules&quot;],&quot;impression&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple intrahepatic nodules, some new compared to prior&quot;],&quot;impression&quot;:&quot;Probable metastases in liver&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis; sacrum; right iliac bone&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar&quot;],&quot;impression&quot;:&quot;Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver; spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct&quot;],&quot;impression&quot;:&quot;Progression of hepatic metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: 350
- name: è¯„ä»·æ³¨å°„ç”¨BL-B01D1åœ¨å¤å‘æˆ–è½¬ç§»æ€§å¦‡ç§‘æ¶æ€§è‚¿ç˜¤ç­‰å¤šç§å®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§ã€è¯ä»£åŠ¨åŠ›å­¦åŠæœ‰æ•ˆæ€§çš„Ib/IIæœŸä¸´åºŠç ”ç©¶
- Reason: Recurrent metastatic ovarian clear cell carcinoma after failure of first-line platinum chemotherapy fits a â‰¥2L recurrent/metastatic gynecologic malignancy trial without biomarker requirement.
- Missing eligibility confirmations (0-2 items):
  - Confirmation of general phase I safety criteria (organ function, ECOG status, etc.)
  - None</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>ğŸ“‹ MDT Discussion Summary (Assistant)</summary>
    <pre>Key Knowledge:
- Platinumâ€‘resistant metastatic highâ€‘grade clear cell ovarian carcinoma with rapid progression in liver, presacral/sacral region, right iliac bone, and mesentery; palliative intent.
- Histology: metastatic highâ€‘grade ovarian clear cell carcinoma, MMR intact, BRCA/HRD negative, germline ATM p.Y316C variant; no current evidence of histologic transformation.
- Marked anemia (Hgb 74 g/L) likely to constrain therapy intensity and prioritized for urgent assessment and correction.
- Existing CT/MR demonstrate extensive pelvic, bone, and hepatic metastatic burden; suspected splenic infarct requires clinical and imaging followâ€‘up.
- Current imaging is adequate for staging; PET/CT may be reserved for scenarios where it would alter systemic or local palliative management.

Controversies:
- Optimal nonâ€‘platinum systemic regimen in platinumâ€‘resistant clear cell histology given significant anemia, unknown ECOG PS, and organ function.
- Added value of FDG PET/CT versus updated contrast CT in a disseminated, palliative setting, and thresholds for when PET/CT would meaningfully change management.
- Scope and timing of local palliative treatments (e.g., radiotherapy to sacral/iliac/presacral and bone lesions) alongside systemic therapy.

Missing Info:
- ECOG performance status and detailed symptom/pain burden, especially from sacral/iliac/presacral and bone disease.
- Full organ function: updated renal profile, full LFTs, coagulation panel.
- Anemia workup and supportive care: transfusion history and plan, iron/B12/folate status, bleeding assessment, thrombosis history (re: possible splenic infarct).
- Detailed prior systemic therapy exposures and toxicities.
- Complete biomarker profile: MSI, TMB, PDâ€‘L1 CPS, HER2, plus any additional HRâ€‘gene data.
- Updated contrastâ€‘enhanced CT chest/abdomen/pelvis and any prior PET/CT (if later performed).

Working Plan:
- Stabilize first: urgently investigate and correct anemia (transfusion and etiologic workup), and complete renal/LFT/coagulation assessment.
- Document ECOG PS and symptom/pain burden to guide treatment intensity and palliative needs.
- Restage with updated contrastâ€‘enhanced CT chest/abdomen/pelvis to reassess hepatic, presacral/sacral, and iliac bone disease and monitor suspected splenic infarct.
- Plan nonâ€‘platinum palliative systemic relapse therapy appropriate for platinumâ€‘resistant clear cell disease, tailored to ECOG PS, organ function, and prior toxicities.
- Obtain additional biomarkers (MSI, TMB, PDâ€‘L1 CPS, HER2) to refine current and future systemic strategies.
- Coordinate palliative local therapy (e.g., radiotherapy) for symptomatic sacral/iliac/presacral and other bone lesions; consider boneâ€‘directed management as indicated.
- Defer FDG PET/CT unless its results are expected to change systemic or local palliative strategy (e.g., mapping symptomatic bone disease or unexpected extraâ€‘abdominal spread).</pre>
    <div class="hint">Structured summary of Key Knowledge, Controversies, Missing Info, and Working Plan.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Please address severe anemia (Hgb 74 g/L) with diagnostic workup and correction before initiating or escalating systemic therapy intensity. [@20230103|5600862 | LAB]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Confirm whether additional staging (e.g., updated wholeâ€‘body CT or PET/CT) would materially change palliative systemic/local treatment planning given recent MR/CT progression. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before we commit to a specific nonâ€‘platinum systemic relapseâ€‘therapy category, I need ECOG PS, detailed pain/symptom burden, and full renal/liver/coagulation profile to assess feasibility in the context of marked anemia (Hgb 74 g/L) [@20230103|5600862 | LAB].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Latest available imaging is from 2022-12-29; no interval CT/MR or PET up to today, so current disease extent and complications (hepatic load, sacral/iliac stability, splenic infarct evolution) are uncertain and updated staging imaging is needed before major treatment changes. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Pathology confirms metastatic highâ€‘grade ovarian clear cell carcinoma; MMR intact and BRCA/HRD negative, with only germline ATM p.Y316C detected on comprehensive NGS [@OH2203828 | Genomics]. MSI, TMB, PDâ€‘L1 CPS, and HER2 status remain undocumented and should be clarified if additional systemic options may depend on these biomarkers [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>No PET/CT has been performed; given rapidly progressive liver, presacral, bone, and mesenteric disease on MR/CT [@2022-12-29|MR | MR] [@2022-12-29|CT | CT], please clarify whether FDG PET/CT would change systemic or local plans before ordering, as guidelines support PET mainly when it will alter management [@pubmed | 23117032].</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Metastatic, platinumâ€‘resistant clear cell ovarian carcinoma with rapid progression in liver, presacral/sacral, iliac bone; palliative intent. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\n- Plan nextâ€‘line systemic therapy suitable for platinumâ€‘resistant disease and prior regimen exposure; avoid reâ€‘challenging with platinum now.\n\n- Critical gaps: ECOG status, pain/symptom burden, prior toxicities, current organ function (renal, full LFTs, coagulation), bone involvement management plan.&quot;,
  &quot;oncologist&quot;: &quot;- Platinum-resistant recurrent clear cell ovarian carcinoma after first-line platinum; systemic relapse-therapy category indicated rather than surveillance or maintenance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].  \n\n- Significant anemia (Hgb 74 g/L) may constrain intensive systemic relapse therapy; needs transfusion/iron workup before regimen choice [@20230103|5600862 | LAB].  \n\n- Missing data: performance status, current symptoms, pain burden, detailed imaging reports, prior treatment toxicities, and full renal/liver function panel.&quot;,
  &quot;radiologist&quot;: &quot;- Progressive presacral pelvic mass (~53Ã—44 mm) with probable sacral and right iliac bone involvement, plus mesenteric peritoneal nodules. [@2022-12-29|MR | MR]  \n\n- Worsening multifocal hepatic metastases; spleen shows patchy low-density area suspicious for infarct, recommend clinical correlation. [@2022-12-29|CT | CT]  \n\n- Disease pattern consistent with metastatic recurrent ovarian malignancy requiring systemic and local control planning. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]&quot;,
  &quot;pathologist&quot;: &quot;- Histology and IHC support metastatic ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, vagina, with nodal metastases, high-grade. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \n\n- MMR proteins intact; BRCA1/2 and HRD negative on comprehensive NGS, with germline ATM p.Y316C variant detected. [@OH2203828 | Genomics]  \n\n- MSI, TMB, HER2, PD-L1 CPS remain unknown; clarify if additional immunotherapy-predictive biomarkers and homologous recombination gene details are available.&quot;,
  &quot;nuclear&quot;: &quot;- No PET/CT metabolic data available; need whole-body FDG PET/CT to assess presacral mass, pelvic nodes, hepatic lesions.  \n\n- Morphologic progression of presacral mass with sacral/iliac involvement and mesenteric nodules suggests increasing locoregional and peritoneal tumor burden [@2022-12-29|MR | MR].  \n\n- CT shows progressive multifocal hepatic metastases; PET would better characterize whole-body metastatic load and potential extra-abdominal disease [@2022-12-29|CT | CT] [@pubmed | 23117032].&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Stabilize patient first: urgently work up and correct anemia and complete renal/LFT/coagulation profile, then assess ECOG and symptom burden. [@20230103|5600862 | LAB]\n\n- Plan nonâ€‘platinum palliative systemic therapy suitable for platinumâ€‘resistant clear cell relapse, intensity tailored to ECOG and organ function. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\n- Clarify MSI, TMB, PDâ€‘L1, HER2 and decide on PET/CT only if results would alter systemic/local strategy (e.g., radiotherapy). [@OH2203828 | Genomics] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]&quot;,
    &quot;oncologist&quot;: &quot;- Urgently evaluate and correct anemia (transfusion, iron/B12/folate workup, bleeding assessment) before initiating nonâ€‘platinum relapseâ€‘therapy in this palliative setting [@20230103|5600862 | LAB] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].  \n\n- After documenting ECOG PS, organ function, and symptom burden, choose a nonâ€‘platinum systemic relapseâ€‘therapy category tailored to platinumâ€‘resistant clear cell disease and current tolerance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].  \n\n- Clarify MSI, TMB, PDâ€‘L1 CPS, and HER2 to refine future systemic strategy, and coordinate palliative local treatments (e.g., radiotherapy) for symptomatic sacral/iliac/presacral and bone disease [@OH2203828 | Genomics] [@2022-12-29|MR | MR] [@2022-12-29|CT | CT] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].&quot;,
    &quot;radiologist&quot;: &quot;- Restage with updated contrast-enhanced CT chest/abdomen/pelvis to reassess hepatic, presacral/sacral, and iliac bone disease burden. [@2022-12-29|MR | MR] [@2022-12-29|CT | CT]  \n\n- Reserve FDG PET/CT for situations where results would change systemic or local palliative strategy, per guideline-based practice. [@pubmed | 23117032]  \n\n- Monitor possible splenic infarct evolution on follow-up imaging; correlate with clinical signs of abdominal pain or thromboembolic disease. [@2022-12-29|CT | CT]&quot;,
    &quot;pathologist&quot;: &quot;- Maintain diagnosis: metastatic highâ€‘grade ovarian clear cell carcinoma with MMR intact, BRCA/HRD negative, germline ATM p.Y316C only. [@OH2203828 | Genomics]  \n\n- Recommend additional biomarker workup (MSI, TMB, PDâ€‘L1 CPS, HER2) to refine systemic strategy in platinumâ€‘resistant relapse. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]  \n\n- No further pathology/IHC or reâ€‘biopsy currently mandated; reassess if clinical course suggests histologic transformation or discordant imaging response.&quot;,
    &quot;nuclear&quot;: &quot;- No prior PET/CT; defer FDG PET/CT unless it would change systemic or local palliative strategy in this disseminated setting [@2022-12-29|MR | MR] [@2022-12-29|CT | CT] [@pubmed | 23117032].  \n\n- Current MR/CT already demonstrate extensive pelvic, bone, and hepatic involvement; these adequately establish advanced metastatic burden for staging purposes [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].  \n\n- If ordered, wholeâ€‘body FDG PET/CT should focus on clarifying symptomatic bone disease extent and unexpected extraâ€‘abdominal metastases that could alter local palliation [@pubmed | 23117032].&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;å¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 43.0 U/L (AST)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.09 mmol/L (NEFA)\nè°·æ°¨é…¸è„±æ°¢é…¶ 4.1 U/L (GLDH)\nç™½è›‹ç™½ 36.7 g/l (ALB)\næ€»è›‹ç™½ 67.0 g/l (TP)\nè°·è‰åŒå·¥é…¶ 12.7 U/L (ASTM)\nçƒè›‹ç™½ 30.3 g/l (GELO)\nç›´æ¥èƒ†çº¢ç´  3.2 umol/l (DBIL)\nå°¿é…¸ 146 umol/l (UA)\næ€»èƒ†çº¢ç´  5.1 umol/l (TBIL)\nå‰ç™½è›‹ç™½ 98 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  1.9 umol/L (IBIL)\nç¢±æ€§ç£·é…¸é…¶ 100.0 U/L (ALP)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 40.8 U/l (ALT)\nè‚Œé… 49 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.21 nan (A/G)\nä¹³é…¸è„±æ°¢é…¶ 254 U/L (LDH)\nå°¿ç´  4.67 mmol/l (UREA)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;å¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 43.0 U/L (AST)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.09 mmol/L (NEFA)\nè°·æ°¨é…¸è„±æ°¢é…¶ 4.1 U/L (GLDH)\nç™½è›‹ç™½ 36.7 g/l (ALB)\næ€»è›‹ç™½ 67.0 g/l (TP)\nè°·è‰åŒå·¥é…¶ 12.7 U/L (ASTM)\nçƒè›‹ç™½ 30.3 g/l (GELO)\nç›´æ¥èƒ†çº¢ç´  3.2 umol/l (DBIL)\nå°¿é…¸ 146 umol/l (UA)\næ€»èƒ†çº¢ç´  5.1 umol/l (TBIL)\nå‰ç™½è›‹ç™½ 98 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  1.9 umol/L (IBIL)\nç¢±æ€§ç£·é…¸é…¶ 100.0 U/L (ALP)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 40.8 U/l (ALT)\nè‚Œé… 49 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.21 nan (A/G)\nä¹³é…¸è„±æ°¢é…¶ 254 U/L (LDH)\nå°¿ç´  4.67 mmol/l (UREA)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2022-7-16ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œç›¸é‚»éª¶éª¨å—ç´¯ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšï¼Œè†€èƒ±å†…å¯ç–‘å°‘è®¸ç§¯æ°”æœ¬æ¬¡ä¸æ˜æ˜¾ã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Recurrent platinum-resistant ovarian clear cell carcinoma with pelvic, liver, peritoneal and possible bone metastases; MSI-stable/MMR-proficient, HRD-negative, BRCA1/2-negative, germline ATM p.Y316C; no major organ dysfunction reported; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6370 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17] [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17]
    to the use of ovarian preservation itself and/or the natural history of the disease (whatever the preservation or not of the ovary) in these patients having poorest prognostic factors). 1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac tumours; 3well and moderatâ€¦
[2] score=0.6264 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17] [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17]
    17 Table 1 Indications for in vivo ovarian tissue preservation in ovarian neoplasms according to the histological type and the stage of the disease STAGE EPITHELIAL OVARIAN NEOPLASMS NON-EPITHELIAL OVARIAN NEOPLASMS BOT1 LGSC LGEC MCexp CCC HGSC HGEC MCinf GCT2 SCC GrCT SLCT3 SLCT4 IA IB IC1 IC2 ## â€¦
[3] score=0.6238 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 6] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6]
    carcinoma demonstrated that adjuvant platinum-based ChT prolonged survival, but did not prospectively evaluate his- tological subtypes.38,39 High-grade EC has a similar prog- nosis to HGSC and is worse than low-grade EC. It is not clear whether there is any survival beneï¬t for adjuvant ChT in stage â€¦
[4] score=0.6234 nccn_ovariancancer_v3_2025__v00000000 [PAGE 22] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]
    Survivorship) Recurrent diseaset Hormonal therapyu or Chemotherapy (if not previously used), see OV-C (6 of 12) or Systemic therapyf,v â€¢ For platinum-sensitive disease, see OV-C (8 of 12) â€¢ For platinum-resistant disease, see OV-C (9 of 12) or Observation f See Principles of Systemic Therapy (OV-C) â€¦
[5] score=0.6211 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]
    with ï¬rst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected â€¦

# PUBMED RAG
(PUBMED: retrieval failed: 500 Server Error: Internal Server Error for url: http://495ga8uy7084.vicp.fun:17088/api/search-paper)</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6369791626930237,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;to the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).\n1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac\ntumours; 3well and moderately differentiated; 4poorly differentiated; #for grade 2-3 imma-\nture teratoma stage II-IV, fertility-sparing data are limited; ## for Sertoli-Leydig cell tumour\nstage IC2-3, fertility-sparing data are limited.\nBOT borderline ovarian tumour; CCC clear cell carcinoma; GCT germ cell tumour; GrCT\ngranulosa cell tumour; HGEC high-grade endometrioid carcinoma; HGSC high-grade serous\ncarcinoma; LGSC low-grade serous carcinoma; LGEC low-grade endometrioid carcinoma,\nMCexp mucinous carcinoma with expansile invasion, MCinf mucinous carcinoma with in-\nfiltrative invasion; SCC small cell carcinoma; SLCT Sertoli-Leydig cell tumour.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6264339089393616,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;17\nTable 1\nIndications for in vivo ovarian tissue preservation in ovarian\nneoplasms according to the histological type and the stage\nof the disease\nSTAGE\nEPITHELIAL OVARIAN NEOPLASMS\nNON-EPITHELIAL OVARIAN NEOPLASMS\nBOT1\nLGSC\nLGEC\nMCexp\nCCC\nHGSC\nHGEC\nMCinf\nGCT2\nSCC\nGrCT\nSLCT3\nSLCT4\nIA\nIB\nIC1\nIC2\n##\nIC3\n##\nII-IV\n#\n\nfavourable oncologic selection criteria for fertility-sparing management as defined in\nthe text (based on the favourable survival and/or recurrence rates observed in cohorts and/\nor comparative studies (radical versus conservative) of patients treated with such characteris-\ntics).\n\noncologic selection criteria acceptable in selected cases (insufficient or conflicting data\nto evaluate accurately the results of the ovarian preservation in this subgroup of patients).\n\nunfavourable oncologic selection criteria for ovarian preservation (poorest survival\nobserved in patients having an ovarian preservation in these subgroups. It could be related\nto the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6237844228744507,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 6,
    &quot;text&quot;: &quot;carcinoma demonstrated that adjuvant platinum-based ChT\nprolonged survival, but did not prospectively evaluate his-\ntological subtypes.38,39 High-grade EC has a similar prog-\nnosis to HGSC and is worse than low-grade EC. It is not clear\nwhether there is any survival beneï¬t for adjuvant ChT in\nstage IA or IB CCC.40,41\nRecommendation\n7.1:\nComplete\nsurgical\nresection\nincluding total abdominal hysterectomy, bilateral salpingo-\noophorectomy, omentectomy, systematic pelvic and para-\naortic lymph node dissection, peritoneal biopsies and\ncytological analysis should be the standard surgical pro-\ncedure in stage I-II high-grade EC, CCC and high-risk\nmucinous ovarian carcinoma [IV, A].\nConsensus: 97% (38) yes, 3% (1) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.2: Patients with stage I-II high-grade\nEC should be offered adjuvant platinum-based ChT [IV, A].\nConsensus: 100% (39) yes, 0% (0) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.3: Adjuvant ChT may be omitted for\nadequately staged IA or IB CCC [IV, C].\nConsensus: 90% (35) yes, 5% (2) no, 5% (2) abstain (39\nvoters)\nRecommendation 7.4: Adjuvant ChT may be considered\nfor stage IC1 CCC [IV, C].&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6233800649642944,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 22,
    &quot;text&quot;: &quot;Survivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\nâ€¢ For platinum-sensitive disease, see OV-C (8 of 12)\nâ€¢ For platinum-resistant disease, see OV-C (9 of 12)\nor\nObservation\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Validated molecular testing should be performed in a CLIA-approved facility\nusing the most recent available tumor tissue. Tumor molecular analysis is\nrecommended to include, at a minimum, tests to identify potential benefit from\ntargeted therapeutics that have tumor-specific or tumor-agnostic benefit including,\nbut not limited to, HER2 status (by IHC), BRCA1/2, HRD status, MSI, MMR,\nTMB, BRAF, FRÎ± (FOLR1), RET, and NTRK if prior testing did not include these\nmarkers. More comprehensive testing may be particularly important in LCOC with\nlimited approved therapeutic options (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6210723519325256,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ï¬rst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciï¬cally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>- Indications for in vivo ovarian tissue preservation in ovarian neoplasms depend on histological subtype (epithelial vs non-epithelial) and FIGO stage, with a structured table outlining when ovarian tissue preservation is or is not recommended for each combination, including borderline tumours, low-grade serous, clear cell, germ cell and sex cordâ€“stromal tumours [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17].

- The ESGO/ESHRE/ESGE fertility-sparing guidance emphasizes that ovarian preservation decisions must account for tumour biology and prognostic factors, noting that some non-epithelial tumours (e.g. immature teratoma, dysgerminoma, yolk sac tumours) and non-invasive peritoneal implants may be compatible with preservation, whereas high-risk histologies or stages generally are not [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17].

- ESGOâ€“ESMOâ€“ESP consensus notes that high-grade endometrioid carcinoma has a prognosis similar to high-grade serous carcinoma and worse than low-grade endometrioid; while platinum-based adjuvant chemotherapy improves survival overall, the survival benefit of adjuvant chemotherapy for stage Iâ€“II high-grade endometrioid disease remains uncertain and should be individualized [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 6].

- NCCN recommends that for recurrent epithelial ovarian cancer, systemic treatment selection (chemotherapy or hormonal therapy) is guided by platinum sensitivity, with distinct pathways for platinum-sensitive vs platinum-resistant disease and an option for observation in selected cases; principles of systemic therapy should be applied when choosing regimens [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].

- ESMO guidelines on epithelial ovarian cancer relapse state that prior cumulative platinum exposure, histotype, BRCA1/2 mutation status, and previous use of PARP inhibitors and/or bevacizumab should determine the choice between PARP inhibitor maintenance and anti-VEGF strategies at recurrence, as these factors influence expected benefit and toxicity [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:12.902790&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:12.903539&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;2a31f255c155&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:13.236380&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:20.652037&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:20.657173&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=åµå·¢ç™Œå¤å‘; histology=é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:44.027973&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Recurrent platinum-resistant ovarian clear cell carcinoma with pelvic, liver, peritoneal and possible bone metastases; MSI-stable/MMR-proficient, HRD-negative, BRCA1/2-negative, germline ATM p.Y316C; no major organ dysfunction reported; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:44.027981&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:44.027983&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 0
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:44.027985&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:51.598172&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:51.598220&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:56.457496&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 551
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:56.457605&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:59.397470&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 559
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:41:59.397549&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:42:03.168487&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 521
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:42:03.168576&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:42:08.208905&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 520
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:42:08.208983&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:42:11.162074&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 501
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:43:28.808412&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2914
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:43:28.809640&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:43:37.535566&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: false
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:43:37.535581&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T18:43:48.298390&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 3595
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
